Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload - Wikidata - wikimedia - TriplyDB

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

http://www.wikidata.org/entity/Q35095396

about

Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease PGC-1 proteins and heart failure The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Ponatinib reduces viability, migration, and functionality of human endothelial cells.Sorafenib cardiotoxicity increases mortality after myocardial infarction.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors Autophagy in hypertensive heart disease Angiogenic biomarkers in children with congenital heart disease: possible implications.PDE5 inhibitor efficacy is estrogen dependent in female heart disease.The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.The impairment of ILK related angiogenesis involved in cardiac maladaptation after infarction.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Sirtuin 1 ablation in endothelial cells is associated with impaired angiogenesis and diastolic dysfunction.The endothelium-dependent effect of RTEF-1 in pressure overload cardiac hypertrophy: role of VEGF-B VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation.Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy AKT signalling in the failing heart Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism.Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice.The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.Autophagy in cardiac plasticity and disease Cardiotoxicity of molecularly targeted agents Cardiac aging: from molecular mechanisms to significance in human health and disease The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype.Adiponectin protects against the development of systolic dysfunction following myocardial infarction.Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice Variable phenotype in murine transverse aortic constriction.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Targeted therapies in breast cancer: are heart and vessels also being targeted?Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice.Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.

P2860

Q26823796-55884261-9056-4ACC-B69F-C322C0288CF5 Q27008861-5E81B62E-A107-42AC-8B19-30B5A2AA1CEB Q27011540-495C721D-FF16-47A3-B7EF-55F1554D26F0 Q28087776-E31A2765-CC37-48A8-AC9A-DF1CB3818E31 Q28115504-46CD1C84-2BFD-4422-99C1-2CC3D594EAF3 Q28250153-4BFA8F6B-E1B7-47E1-A1F2-68FA48F47C77 Q28507674-01757D91-EC82-4B86-97CA-94402F6F6932 Q28509556-12102147-A1AA-42B4-9260-B8949E047B43 Q28575727-5F0E3ECB-1ABC-41F6-89F6-95D328842758 Q30426853-CFB74E9E-D3BF-472F-98DE-00111F744ED2 Q33364077-D9F43D6A-60DA-4A8E-966A-6A95D3A17941 Q33681995-092EBAE1-548B-4E17-98CC-454286A190C5 Q33698419-7082A01E-78C1-4C81-AB82-4D332461DFB1 Q33726330-78D59345-00F8-49A6-A6BA-AB9E5E347C21 Q33869129-32034A31-8184-4246-A1D0-07A158782A67 Q33872491-75E88A34-DD9A-4277-881D-3FF552485FD7 Q33876378-14688B7F-7E18-42D5-9058-A29BBAA37BE0 Q33912715-7E76452A-A48C-4869-BF5A-BAADA45FB9A8 Q34031262-305AFE14-1E8C-44A7-AA8E-37A5560C757E Q34554398-97EC85F0-0D42-4C20-B5FA-2B1E4847EB69 Q34724614-8F65CE18-D04F-4843-971F-B29CF7D6C851 Q34726894-BEEFC4B9-4589-462C-B58D-3B8DCB229EED Q34808450-40C5DA35-7DB1-4FDC-87FE-7768E1C2361D Q34980825-1DD51B55-B2D8-4E6B-BB4B-75C5953E997D Q35003522-AB0F7F2A-1B1C-4E07-8011-1A18EFC3D7B2 Q35128548-3E301E4C-686B-4678-B2D1-43F4F41E828C Q35135394-DE5D6E0D-8A32-49FF-B387-F63A747D7B9B Q35135731-AB68463A-7DF4-4938-A62A-B4B5C97DED98 Q35354723-167EF379-A485-47F4-BBC7-A8DF31783976 Q35777997-F3C8B8CB-E704-43D6-96E7-9FA2A52631B9 Q35878459-549F9023-3812-459A-A5EC-EBD46E12369A Q35898648-DCC5C847-4223-4354-8C2C-AE2F3B754802 Q35961854-0A215361-BBE2-4640-ACC3-8387DC4348C4 Q36004798-A7E5A5A8-11E1-434A-8609-2188D5AC75D3 Q36099401-CC3904F7-875D-4F23-8161-38EFAFA625C5 Q36141950-A82087A6-46C0-44B4-B9CE-6E2DB5424E16 Q36163040-3844F94E-7169-493B-BB93-9999C32416D6 Q36245324-CA54E3AD-566D-489D-A8D6-F569C580EA29 Q36267201-AF2D7450-61C8-4FF0-B816-3BA37F9BD7FA Q36281111-2888E251-01AB-4077-B37C-1B40CB1ED654

P2860

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

http://www.wikidata.org/entity/Q35095396

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Vascular endothelial growth fa ...... response to pressure overload

@ast

Vascular endothelial growth fa ...... response to pressure overload

@en

type

label

Vascular endothelial growth fa ...... response to pressure overload

@ast

Vascular endothelial growth fa ...... response to pressure overload

@en

prefLabel

Vascular endothelial growth fa ...... response to pressure overload

@ast

Vascular endothelial growth fa ...... response to pressure overload

@en

P1433

Q35095396-AB8D27A3-BA0D-4B64-8C16-B8DFD2A209E4

P1476

Q35095396-9BA5D01A-1215-4066-86E3-0EFD11A510E5

P2093

Q35095396-015E0BBC-5A4C-4B33-8D6B-394C9900B1FD

Q35095396-2FCABEDD-0419-4563-BC29-0FEE021C0694

Q35095396-3BCFB183-B6B8-4035-8443-13DE37EEACEB

Q35095396-830917AE-A9A3-4234-B250-21363F5AA71B

Q35095396-90566E9B-A6AD-4E0A-9A1B-2B7BCBDAF765

Q35095396-DE0DA5C9-E90E-417B-A6DE-470A71C9DDC0

P2860

Q35095396-1D486E26-6C30-4979-B97E-A561616E264A

Q35095396-22162751-5661-44CA-9585-8C85D5AECCE2

Q35095396-22F93BFC-264D-4938-AD77-93CC6BE448F9

Q35095396-246C5122-46A1-49DF-8830-6C96199BF7A0

Q35095396-250AD66D-2E60-4038-BC60-D9FCD577B4E3

Q35095396-29B84DCE-1D03-4583-9569-320C9FF50C14

Q35095396-2D08B421-254B-481E-A999-77C533FE8260

Q35095396-37BB2B06-F782-478E-9D68-326401A4964D

Q35095396-3C256D15-D239-4F63-9EFA-BDB5FA113B1D

Q35095396-3D5EEAAE-9352-4C13-AD72-F3C2510F5E8F

P304

Q35095396-BFA7EF22-953E-4C36-975E-1D876606B8AB

P31

Q35095396-5E21AA44-0F40-4B94-82CC-56587ECC510C

P356

Q35095396-24F4E86A-B6B9-470E-9503-CE7DC59763A7

P407

Q35095396-66D99783-F4BF-4A90-8150-2902F9455017

P433

Q35095396-EA25145B-A068-4E5A-9435-E25894D78A53

P478

Q35095396-5FAA4E1C-CD0A-43DD-932D-55F6AC64C828

P577

Q35095396-57D04121-37B3-4C8F-AAC3-B70CA7D8825E

P698

Q35095396-9551A19E-5DD0-43C3-819B-A43D7AE67DD7

P921

Q35095396-ACF1ED65-95DA-4E4F-BD8D-CFB9865F23E9

P932

Q35095396-EF3322E9-BA44-4CBE-AEC8-54149A910B9A

P356

01.HYP.0000215207.54689.31

P1433

P1476

Vascular endothelial growth fa ...... response to pressure overload

@en

P2093

Douglas B Sawyer

http://www.w3.org/2001/XMLSchema#string

Ichiro Shiojima

http://www.w3.org/2001/XMLSchema#string

Kaori Sato

http://www.w3.org/2001/XMLSchema#string

Kenneth Walsh

http://www.w3.org/2001/XMLSchema#string

Wilson S Colucci

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Izumiya

http://www.w3.org/2001/XMLSchema#string

P2860

Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes

Fibroblast growth factor-2 mediates pressure-induced hypertrophic response

Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy

Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188

Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia.

Adiponectin-mediated modulation of hypertrophic signals in the heart

Molecular and biological properties of vascular endothelial growth factor.

Adipose tissue mass can be regulated through the vasculature.

Angiogenesis in skeletal and cardiac muscle.

AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle.

P304

887-893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.HYP.0000215207.54689.31

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16567591

http://www.w3.org/2001/XMLSchema#string

P921

P932

3132898

http://www.w3.org/2001/XMLSchema#string